Cover Image
市場調查報告書

細胞週期蛋白依賴性激酶6:開發中產品分析

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 409622
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
細胞週期蛋白依賴性激酶6:開發中產品分析 Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H1 2018
出版日期: 2018年02月27日 內容資訊: 英文 110 Pages
簡介

本報告提供以細胞週期蛋白依賴性激酶6為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供你涵括最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

細胞週期蛋白依賴性激酶6 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Beta Pharma Inc
  • Eli Lilly and Company
  • FLX Bio, Inc.
  • G1 Therapeutics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Novartis AG
  • Onconova Therapeutics Inc
  • Pfizer Inc
  • TEIJIN FIBERS製藥
  • ViroStatics srl
  • XuanZhu Pharma Co Ltd

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1325TDB

Summary:

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Cell division protein kinase 6 (CDK6) is an enzyme encoded by the CDK6 gene. It is involved in initiation and maintenance of cell cycle exit during cell differentiation, prevents cell proliferation and regulates negatively cell differentiation. It is required during thymocyte development. It promotes the production of newborn neurons, probably by modulating G1 length, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. It prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation-activity.

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 2, 1, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas which include indications Breast Cancer, Metastatic Breast Cancer, Mantle Cell Lymphoma, Colorectal Cancer, Lymphoma, Non-Small Cell Lung Cancer, Liposarcoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Oligodendroglioma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Glioblastoma Multiforme (GBM), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), AIDS - Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, B-Cell Leukemia, Brain Tumor, Chemotherapy Induced Myelosuppression, Chordoma, Colon Cancer, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Fallopian Tube Cancer, Gastric Cancer, Germ Cell Tumors, Glioblastoma Multiforme (GBM), Glioma, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leukemias, Melanoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Ovarian Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Neuroendocrine Tumors, Peritoneal Cancer, Primary CNS Lymphoma, Prostate Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis, Small-Cell Lung Cancer, Solid Tumor, Squamous Non-Small Cell Lung Cancer, Thymic Carcinoma and Unspecified B-Cell Lymphomas.

The latest report Cyclin Dependent Kinase 6 - Pipeline Review, H1 2018, outlays comprehensive information on the Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)
  • The report reviews Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Overview
    • Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
    • Beta Pharma Inc
    • Eli Lilly and Co
    • G1 Therapeutics Inc
    • Jiangsu Hengrui Medicine Co Ltd
    • MEI Pharma Inc
    • Novartis AG
    • Onconova Therapeutics Inc
    • Pfizer Inc
    • Sihuan Pharmaceutical Holdings Group Ltd
    • Teijin Pharma Ltd
    • ViroStatics srl
  • Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Drug Profiles
    • abemaciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPI-1178 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-1T38 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GZ-381 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HEC-80797 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ON-123300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palbociclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ribociclib succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHR-6390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRX-3177 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trilaciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • voruciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-2370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XZP-3287 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Dormant Products
  • Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Discontinued Products
  • Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 15, 2018: Quebec and New Brunswick Become First Provinces to Provide Public Funding of IBRANCE for the First-Line Treatment of Metastatic Breast Cancer
      • Jan 08, 2018: MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib
      • Jan 03, 2018: Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
      • Dec 21, 2017: MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
      • Dec 13, 2017: First-line Ribociclib Improves PFS in Pre- and Peri-menopausal Women with HR-positive, HER2-negative Advanced Breast Cancer
      • Dec 12, 2017: SMC has recommended Ibrance(palbociclib) for use within NHS Scotland for previously untreated HR+/HER2- metastatic breast cancer
      • Dec 11, 2017: Ibrance is accepted for restricted use within NHS Scotland
      • Dec 06, 2017: Updated Data From Phase 3 Trial Of IBRANCE (Palbociclib) Plus Letrozole In Er+, Her2- Metastatic Breast Cancer Confirm Improvement In Progression-Free Survival
      • Dec 06, 2017: Kisqali first and only CDK4/6 inhibitor to show superior efficacy vs. oral endocrine therapy as 1L treatment in randomized Phase III trial in premenopausal women with HR+/HER2- advanced breast cancer
      • Nov 23, 2017: Researchers at Washington University report: DiviTum can evaluate the biologic activity of blockbuster breast cancer drug after two weeks
      • Nov 16, 2017: Novartis Advanced Breast Cancer Drug Kisqali (ribociclib) is First Cancer Treatment Recommended by NICE Under Updated Cancer Appraisal Process
      • Nov 14, 2017: Novartis To Present Data on Breast Cancer Drug Ribociclib At Upcoming 40th Annual San Antonio Breast Cancer Symposium (SABCS)
      • Nov 08, 2017: Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
      • Nov 06, 2017: G1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell Response
      • Nov 03, 2017: Pancreatic cancer patients to benefit from breast cancer drug
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Beta Pharma Inc, H1 2018
  • Pipeline by Eli Lilly and Co, H1 2018
  • Pipeline by G1 Therapeutics Inc, H1 2018
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
  • Pipeline by MEI Pharma Inc, H1 2018
  • Pipeline by Novartis AG, H1 2018
  • Pipeline by Onconova Therapeutics Inc, H1 2018
  • Pipeline by Pfizer Inc, H1 2018
  • Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H1 2018
  • Pipeline by Teijin Pharma Ltd, H1 2018
  • Pipeline by ViroStatics srl, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
Back to Top